Follow us on:

N4 Pharma MTAs demonstrate commercial interest (Analyst Interview)

Giles
July 19, 2021
10:41 am

N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst Vadim Alexandre joins DirectorsTalk. Vadim talks us through the main points of their latest research note, explains what the current vaccine landscape means for the company, why someone might want to invest in the company and what can be expected from N4 over the coming months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

N4 Pharma Nuvec® has Considerable Potential in Developing Novel Cancer Treatments (VIDEO) December 11, 2023
N4 Pharma CEO Nigel Theobald excited with siRNA programme (VIDEO) March 13, 2023
N4 Pharma plans for commercialising Nuvec (VIDEO) September 15, 2022
N4 Pharma encouraging data, oncology the quickest route to clinic (Interview) January 26, 2022
N4 Pharma a deeper understanding of the capabilities of Nuvec (Interview) September 21, 2021
N4 Pharma Nuvec showing fantastic results (Interview) May 24, 2021
N4 Pharma Make considerable progress on Nuvec, well positioned for collaborations (Interview) February 25, 2021
N4 Pharma could attract a corporate partner far earlier than expected says SP Angel (Analyst Interview) November 19, 2020
N4 Pharma optimisation work shows the versatility of Nuvec (Interview) November 6, 2020
N4 Pharma in very good shape as it moves forward (Interview) September 18, 2020

More News

N4 Pharma to host webinar on collaboration agreement with SRI International April 26, 2024
N4 Pharma collaborates with SRI International to combine Nuvec and FOX Three MGS technology April 25, 2024
N4 Pharma achieves material advancements in the capabilities of Nuvec® April 23, 2024
N4 Pharma provides Positive Update on Nuvec® oral delivery research April 18, 2024
N4 Pharma provides encouraging update on its ongoing in vitro siRNA research work February 15, 2024
N4 Pharma’s Nuvec® granted patent in India January 19, 2024
N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment January 16, 2024
N4 Pharma updates on Nuvec AAV Viral Vector research January 8, 2024
N4 Pharma plc Nuvec Oral Delivery Update December 18, 2023
N4 Pharma plc Nuvec® R&D and Strategy Update December 7, 2023

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.